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Background: Cervical cancer is the third most common cancer in women worldwide. The most common
histopathological subtype is cervical squamous cell carcinoma (SCC, 75-80%), followed by adenocarcinoma (AC) and
adenosquamous carcinoma (ASC; together 15-20%). Rising incidence rates of AC have been observed relative and
absolute to SCC and evidence is accumulating that cervical AC is a distinct clinical entity. Cervical SCC, ASC, and AC
are caused by a persistent infection with high-risk human papillomavirus (HPV) and failed control of the immune
system plays a pivotal role in the carcinogenesis of all three histopathological subtypes. Human leukocyte antigen E
(HLA-E), a non-classical HLA class Ib molecule, plays an important role in immune surveillance and immune escape
of virally infected cells. In this study we investigated HLA-E expression in three well-defined cohorts of cervical AC,
ASC, and SCC patients, and determined whether HLA-E expression was associated with histopathological
parameters and patient survival.
Methods and results: HLA-E expression was assessed by immunohistochemistry on formalin-fixed,
paraffin-embedded tissue sections of 79 SCC, 38 ASC, and 75 AC patients. All patients included were International
Federation of Gynaecology and Obstetrics stage I-II and underwent radical hysterectomy with lymphadenectomy as
primary treatment. Significant differences between the histopathological subgroups were detected for age
distribution, HPV positivity, HPV type distribution, tumour size, tumour infiltration depth, lymph-vascular space
invasion, and adjuvant radiotherapy. High expression of HLA-E was found in 107/192 (56%) cervical carcinomas,
with significantly more overexpression in cervical AC compared to SCC and ASC (37/79 SCC, 18/38 ASC, and 52/
75 AC; P= 0.010). High HLA-E expression in cervical AC was associated with favourable long term disease-specific
and recurrence-free survival (P= 0.005 and P= 0.001, respectively).
Conclusion: High expression of HLA-E occurred in the majority of all histopathological subtypes of cervical cancer;
especially in cervical AC. High HLA-E expression in cervical AC was associated with improved patient survival. This
study also highlights the importance of careful evaluation of cervical carcinomas to distinguish histopathological
subtypes. In the future, insight into the biological behaviour and distinct molecular carcinogenetic processes of the
AC, ASC, and SCC subtypes may contribute to the development of more tumour-specific treatment strategies.
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Cervical cancer is the third most common cancer and
fourth leading cause of cancer death in women worldwide
[1]. Invasive carcinomas of the cervix are classified into
subtypes based on their histological features. Cervical
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reproduction in any medium, provided the or75-80% of all cervical carcinomas and is the most com-
mon histological variant, followed by cervical adenocar-
cinoma (AC) and adenosquamous carcinoma (ASC),
together comprising approximately 15-20% of all cervical
carcinomas [2-4]. The overall incidence of invasive cer-
vical cancer, particularly that of SCC, has declined in
developed countries since the introduction of cytological
screening programmes that have improved detection of
premalignant stages. In contrast, the absolute and relative
incidence rates of AC and ASC have been stable or haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ades. This trend was observed predominantly in younger
women and in developed countries [5-10].
The rising incidence of AC has resulted in a heigh-
tened interest in this tumour subtype. AC differs from
ASC and from SCC not only in histological features, but
also in biological behaviour, patterns of tumour growth,
metastasis, and sensitivity to chemo- and radiotherapy
[11,12]. Furthermore, compared to SCC, AC and ASC
are associated with worse prognosis and survival, with
higher recurrence rates, and with different responses to
similar treatment strategies [10,11].
Concerning aetiology, AC, ASC, and SCC have one
foremost aspect in common: they are caused by a per-
sistent cervical infection with high-risk human papillo-
mavirus (HPV) [13-15]. The immune system plays a
pivotal role in cervical carcinogenesis. Although most
HPV infections are transient and efficiently cleared by
the immune system, a small percentage of infected
women develop premalignant lesions and eventually in-
vasive cervical cancer. The progression from HPV infec-
tion to persistent infection to invasive cervical cancer is
largely determined by failed control of the immune sys-
tem and by the ingenuity of the infected (tumour) cells
in escaping the host’s immune surveillance [16,17].
Human leukocyte antigen E (HLA-E) is a non-classical
major histocompatibility complex class I molecule [18].
HLA-E can be expressed on the cell surface of nucleated
cells and presents a limited variety of peptides to cyto-
toxic T lymphocytes (CTLs) and natural killer (NK)
cells. Compared to the classical HLA class I molecules
(HLA-A, -B, -C), HLA-E is almost non-polymorphic and
has low cell surface expression in normal tissues [18].
Upregulation of HLA-E on the cell surface and conse-
quent recognition by CTLs and NKs lead to either an in-
hibitory or a stimulatory response, depending on
subsequent receptor binding and the intended cytotoxic
response [18]. Binding to the CD94/NKG2A receptor
leads to an inhibitory response, whereas binding to the
CD94/NKG2C receptor leads to a stimulatory response.
The first large studies concerning the function of HLA-E
addressed maternal-foetal interaction in pregnancy.
Expressed on placental tissue, HLA-E plays an important
role in pregnancy and enables the mother’s immune sys-
tem to accept the foetus, which would otherwise be
detected as “foreign” [19]. Additional studies provided
evidence that HLA-E expression contributes to immune
surveillance and/or immune escape of virally infected
cells, stressed cells, and tumour cells [18,20-22].
HLA-E is only weakly expressed in normal cervical
epithelium [23]. HLA-E expression was found to in-
crease significantly with the progression from normal
epithelium to virally infected lesions to cervical intrae-
pithelial neoplasia grade 1, grade 2–3, and cervicalcancer [24]. In 83% of cervical cancer samples, HLA-E
expression was higher in tumour cells compared to the
paired normal cervical epithelium [23]. Gooden et al.
analysed 149 cervical carcinoma patients for HLA-E ex-
pression [23]; and although the research did not focus
on analysis of differences by histopathological subtypes,
only 4/26 (15%) AC/ASC cases exhibited low expression
of HLA-E compared to 29/123 (24%) of the SCC cases.
This difference in HLA-E expression between the histo-
logical subtypes was remarkable and motivated investi-
gation of the role of HLA-E in the AC and ASC
subtypes of cervical cancer.
Given the rising incidence rates of cervical AC, it is
important to further distinguish the biological behaviour
and molecular carcinogenesis of AC compared to SCC
and ASC. Insight in these processes further defines cer-
vical AC as a distinct clinical entity and may lead to the
design of more tumour-specific treatment strategies to
fight this specific tumour subtype.
Here, for the first time, we report the expression of
HLA-E in a large and well-defined cohort of cervical AC
patients and compare this expression with our previous
measurements of HLA-E expression in cervical SCC and
ASC. Furthermore, we investigate the associations be-
tween HLA-E expression, clinicopathological para-
meters, and disease-specific and recurrence-free survival
of these cervical cancer patients. In this well-defined co-
hort of cervical AC patients, HLA-E is more frequently
overexpressed than in cervical SCC and ASC. High ex-
pression of HLA-E in AC patients was found to be asso-
ciated with improved long-term disease-specific and
recurrence-free survival.
Methods
Patients
This study included a total of 192 women who were
diagnosed with primary carcinoma of the uterine cervix.
We included all AC and ASC patients and a selected co-
hort of SCC patients, all FIGO (International Federation
of Gynaecology and Obstetrics) stage I-II, who under-
went radical hysterectomy with lymphadenectomy as
primary treatment between January 1990 and December
2005 at the Leiden University Medical Centre. Patients
who had received radiotherapy and/or chemotherapy
prior to surgery were excluded. Formalin-fixed, paraffin-
embedded tissue blocks containing a representative part
of the resected cervical tumour were retrieved from the
archives of the Department of Pathology. Conventional
histology sections were stained with haematoxylin and
eosin and reviewed by a trained pathologist (GJF). Cases
with deficient representative tumour material were
excluded from further study. Additionally, to carefully
discriminate SCC from ASC, conventional histology sec-
tions were stained with Periodic Acid Schiff Plus and
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staining patterns of intra-cytoplasmic mucus were
(re)classified as ASC. The following rare histological var-
iants of cervical carcinoma were excluded because their
relation with HPV infection is less well established: clear
cell AC (N=6), serous AC (N=2), mesonephric AC
(N=2), minimal deviation AC (N=4), glassy cell carcin-
oma variant (N=4), adenoid carcinoma (N=1), neuroen-
docrine carcinoma (N=2), undifferentiated carcinoma
(N=2), mesenchymal carcinoma (N=1), and mixed car-
cinoma (N=9). The final study cohort consisted of 75 AC
cases, 35 ASC cases and 79 SCC cases. This distribution
of tumour subtypes is not a reflection of the population
distribution (80% SCC versus 20% AC/ASC); however, as
we were especially interested in the cervical AC and ASC
subtypes, a smaller SCC cohort was considered sufficient
for valid comparisons.
Clinical charts and the original pathology reports for all
192 patients were reviewed and the following data were
collected: age of the patient at date of primary treatment
(surgery), FIGO stage, tumour size, infiltration depth,
lymph-vascular space invasion (LVSI), tumour infiltration
in the parametria, tumour-positivity of the resection mar-
gins, presence of lymph node metastases, and whether the
patient had received postoperative radiotherapy. Follow-
up data for all patients were collected concerning survival
and recurrence of the disease. Disease-specific survival
was defined as time in months from date of primary sur-
gery until death by cervical cancer or until date of last fol-
low-up. Recurrence-free survival was defined as time in
months from date of primary surgery until date of first re-
currence or date of last follow-up in case of no recurrence.
All human tissue samples were used in accordance with
the guidelines of the Ethical Committee of the Leiden
University Medical Center.
HPV typing
All cervical tumour samples included in this study were
typed for HPV as described previously [25]. DNA was
extracted from the formalin-fixed, paraffin-embedded
tissue blocks. Sections of a paraffin block without tissue
were cut between each sample to rule out contamination
and to use as a negative control. HPV DNA was ampli-
fied using the SPF10 primer set. HPV DNA detection
and broad spectrum HPV genotyping were performed
using the INNO-LiPA HPV genotyping Extra line probe
assay (Innogenetics, Ghent, Belgium), which is a highly
sensitive hybridisation assay for detecting HPV DNA
and specifying HPV genotypes.
Immunohistochemistry
Clone MEM-E/02 mouse monoclonal antibody against
HLA-E (MCA2193, AbD Serotec, Kidlington, UK) was
used to determine HLA-E protein expression in tumourcells from all patients included in this study (N= 192). A
previously described tissue microarray (TMA) [26] in-
cluding tissue cores from 15 AC patients and all SCC
(N= 79) and ASC (N= 38) patients was used to deter-
mine HLA-E protein expression of the tumour cells
(partly described previously by Gooden et al [23]). To
obtain a high concordance rate with whole tissue slides,
only samples with a minimum of two representative tis-
sue cores, both of which contained a minimum of 20%
tumour tissue, were used. HLA-E protein expression in
all AC patients included in this study (N= 75) was deter-
mined on whole tissue sections (4-μm paraffin sections).
To verify the comparability of the staining patterns of
the TMA and the whole-section stains, 15 AC cases
were included on the TMA and were also stained as
whole sections; this analysis resulted in highly compar-
able measurements (mean total score TMA staining
6.13 ± 1.8, mean total score whole section staining
6.00 ± 1.4, P= 0.956).
First, the tissue sections were deparaffinised and rehy-
drated using graded concentrations of ethanol to distilled
water; endogenous peroxidise activity was blocked with
0.03% H2O2/MeOH for 20 minutes. Antigen retrieval
was performed in boiling 0.01 M citrate buffer (pH 6.0)
for 12 minutes. After two hours of cooling in citrate buf-
fer, slides were washed twice in distilled water and twice
in phosphate-buffered saline. Subsequently incubation
was performed overnight at room temperature with the
primary antibody diluted 1:800 in phosphate-buffered sa-
line containing 1% bovine serum albumin. Second, sec-
tions were incubated with BrightVision poly-horseradish
peroxidase anti-mouse/rabbit/rat IgG (ImmunoLogic BV,
Duiven, the Netherlands) for 30 minutes at room
temperature. Washing between incubations was per-
formed three times for five minutes in phosphate-
buffered saline. Immune complexes were visualized by
applying a 0.05 M Tris–HCl buffer (pH 7.6) containing
0.05% of 3,3’-diamino-benzidine-tetrahydrochloride and
0.0018% H2O2. After 10 minutes, the reaction was
stopped by rinsing with demineralised water. Finally, the
tissue sections were counterstained with Mayer’s haema-
toxylin before addition of a coverslip. Brown cytoplasm
and membrane staining of tumour cells indicated positive
HLA-E expression. Resident leukocytes and endothelium
of local blood vessels were used as internal positive con-
trols, and two extra AC sections stained without primary
antibodies were used as negative controls.
Immunohistochemical evaluation
The staining patterns were scored semi-quantitatively
without prior knowledge of clinical and histopathological
parameters with the scoring system proposed by Ruiter
et al [27]. The percentage of positively stained tumour
cells was scored from 0 to 5 to indicate the presence of
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(1-5%, 1), local (6-25%, 2), occasional (26-50%, 3), major-
ity (51-75%, 4), or large majority (>75%, 5). The staining
intensity of positively stained tumour cells was scored
from 0 to 3 to reflect negative (0), weak (1), moderate
(2), or strong (3) staining intensity. A final score was cal-
culated by totalling the scores for percentage and inten-
sity, resulting in a score from 0 to 8. A final score of 0
indicated negative expression, 2–4 weak expression, 5–6
moderate expression, and 7–8 strong expression.Statistics
Statistical analysis was carried out with IBM SPSS Statis-
tics 20.0 for Windows (IBM Corporation, Armonk, NY,
USA). Data were processed using the Chi-square test for
categorical variables, Student’s t-test for parametric con-
tinuous variables, or one-way analysis of variance for nu-
merical data when comparing more than two groups.
The Spearman rho correlation coefficient was used to
detect correlation in nonparametric data, and the Pear-
son correlation coefficient was used in cases of normal-
ity. Kaplan-Meier survival curves were generated using
GraphPad Prism 5.04 (GraphPad Software Inc., LA Jolla,
CA, USA) to estimate disease-specific and recurrence-Table 1 Patient and tumour characteristics by histopathologi
SCC
n=79
Age (years), mean± sd 49.8 ± 14.5
(95% CI for mean) (46.6-53.1)
FIGO stage I, n (%) 64 (81)
FIGO stage II, n (%) 15 (19)
High-risk HPV positive, n (%) 75 (95)
- HPV 16 51 (68)
- HPV 18 13 (17)
- Other 11 (15)
Tumour size≥ 40 mm, n (%) 31 (41)
Infiltration depth≥ 15 mm, n (%) 39 (51)
Positive LVSI, n (%) 47 (60)
Positive resection margins, n (%) 22 (28)
Positive parametria, n (%) 8 (10)
Positive lymph nodes, n (%) 27 (34)
Adjuvant radiotherapy, n (%) 48 (61)
Follow-up time (months), mean± sd 199.4 ± 11.9
(95% CI for mean) (176.1-222.6)
Recurrence-free time (months), mean± sd 184.2 ± 12.4
(95% CI for mean) (160.0-208.4)
Death, all causes, n (%) 34 (43)
Death by tumour, n (%) 19 (24)
Recurrent disease, n (%) 21 (27)
P values were calculated using the Pearson Chi-square test for categorical data and
disease-free time were calculated by the Log Rank (Mantel-Cox) test for the histopa
statistically significant (P< 0.05). For nine, six, eighteen, and one cases the tumour s
positivity of resection margins, respectively, could not be identified. SCC, cervical sq
adenocarcinoma; FIGO, International Federation of Gynaecology and Obstetrics; HPfree survival, and the Log Rank test was used to analyse
between-group differences in survival. A multivariate
analysis was performed using a Cox proportional hazard
model with stepwise regression. For all reported tests, P
values were two-sided and P values <0.05 were consid-
ered to indicate statistical significance.Results
Patients and survival
A total of 192 patients (median age 44 years, range 24–
87 years) were included in this study: 79 (41%) with
SCC, 38 (20%) with ASC, and 75 (39%) with AC. Patient
and tumour characteristics for the three histological
tumour subtypes are presented in Table 1. Significant
differences were detected between SCC, ASC, and AC in
age distribution, with ASC and AC presenting at relatively
younger age (mean age 50, 43 and 45 years, for SCC, ASC
and AC respectively; P=0.014). For SCC and ASC, mean
tumour size as well as mean tumour infiltration depth
were significantly larger than AC, with mean tumour sizes
of 37± 16 mm, 35± 16 mm, and 26± 14 mm, respectively
(95% confidence intervals (CIs) 34–41 mm, 30–40 mm,
and 23–30 mm, respectively; P< 0.001) and mean infiltra-
tion depths of 15± 7 mm, 15± 10 mm, and 11± 7 mm,cal subtypes
ASC AC P
valuen= 38 n=75
43.0 ± 11.7 44.7 ± 13.3 0.014
(39.1-46.8) (41.6-47.7)
34 (89) 67 (89) 0.260
4 (11) 8 (11)
37 (97) 64 (85) 0.036
19 (51) 28 (44) 0.003
12 (32) 28 (44)
6 (16) 8 (12)
16 (42) 11 (16) 0.001
13 (34) 17 (24) 0.003
19 (53) 23 (38) 0.037
4 (11) 17 (23) 0.109
4 (11) 4 (5) 0.483
9 (24) 15 (20) 0.125
18 (47) 30 (40) 0.034
186.3 ± 16.6 201.9 ± 11.0 0.782
(153.9-218.8) (180.3-223.5)
168.3 ± 17.6 148.2 ± 10.5 0.977
(133.8-202.8) (127.5-168.8)
12 (32) 22 (29) 0.177
10 (26) 16 (21) 0.828
10 (26) 19 (24) 0.984
one-way analysis of variance for numerical data. Total follow-up time and
thological subgroups separately. P values in bold type were considered
ize, depth of infiltration, LVSI (lymph-vascular space invasion), and tumour
uamous cell carcinoma; ASC, cervical adenosquamous carcinoma; AC, cervical
V, human papillomavirus; CI, confidence interval.
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12 mm, respectively; P= 0.001).
A total of 96/192 (50%) patients were treated with ad-
juvant radiotherapy. Adjuvant radiotherapy was indi-
cated in cases with tumour-positive lymph nodes (51/
192, 27%), tumour infiltration in the parametria (16/192,
8%), tumour-positive resection margins (43/191, 23%),
or if two out of three of the following unfavourable
prognostic factors were present: LVSI (89/174, 51%),
tumour size ≥40 mm (58/183, 32%), and tumour infiltra-
tion depth ≥15 mm (69/186, 37%). Follow-up data were
collected until December 2011. By that date, the esti-
mated mean disease-specific survival for all patients (in-
dependent of histological subtype) was 202 ± 7.4 months
(95% CI 188–217 months) and the estimated mean
recurrence-free survival for all patients was
183 ± 8.1 months (95% CI 167–198 months). Fifty
patients (26%) had suffered from recurrent disease,
45 patients (23%) had died due to cervical cancer, and
23 patients (12%) had died due to other causes. Survival
data per histological subtype are presented in Table 1.
No significant differences in disease-specific and
recurrence-free survival between the histological sub-
types were detected by univariate analysis. However, in
multivariate Cox regression analysis, histopathological
subtype was an independent predictor for disease-
specific and recurrence-free survival, as were the pres-
ence of lymph node metastasis, tumour size, and
tumour-infiltrated parametria. Age, infiltration depth,
LVSI, tumour-positive resection margins, postoperative
radiotherapy, and FIGO stage were not independent pre-
dictors for survival in the multivariate analysis.
HPV types
All tumour samples included in this study were typed for
HPV. High-risk HPV types were detected in 176/192
(92%) patients. HPV 16 and HPV 18 were the most fre-
quent genotypes, identified in 98 (51%) and 53 (28%)
patients, respectively. Twenty-five (13%) patients were
positive for other high-risk HPV types: eight for HPV 45,
four for HPV 52, four for HPV 33, three for HPV 31, two
for HPV 68, and four single cases for HPVs 51, 56, 58, and
59. Overall, HPV positivity was more frequently detected
in SCC and ASC than in AC (95% and 97% versus 85%,
P=0.036). Furthermore, the HPV type distribution was
significantly different for all three histological subtypes
(P=0.003), with HPV 16 more dominant in SCC than
HPV 18 (68% vs. 17%), while HPVs 16 and 18 were
detected with equal frequency in AC (44% vs. 44%;
Table 1).
HLA-E (MEM-E/02) expression
HLA-E expression was determined in all 192 patients
with the HLA-E-specific MEM-E/02 antibody. For 133cervical cancer patients, HLA-E expression was assessed
via tissue cores confined in a TMA; for 74 cervical AC
patients, expression was assessed in whole tissue sec-
tions (15 AC cases overlap). All negative controls were
negative and internal controls (endothelium of local
blood vessels and resident leukocytes) were positive for
HLA-E. The normal cervical epithelia, when present,
were all weakly positive for HLA-E, in accordance with
previous reports [23,24] (Figure 1A and B).
Examples of positive and negative HLA-E expression
patterns in cervical carcinomas are depicted in Figure 1
C-I. Staining patterns exhibiting high HLA-E protein
expression were detected in the majority of cervical
carcinomas. In percentage, 102/192 (53%) carcinomas
showed more than 75% of positively stained tumour
cells and another 50/192 (26%) carcinomas showed 50-
75% of positively stained tumour cells. The intensity of
staining varied from weak (in 40%) to moderate (in
34%) to strong (in 15%). Twenty-three (12%) carcin-
omas scored completely negative, including 12/79 SCC,
9/38 ASC, and 2/75 AC samples (15%, 24%, and 3%,
respectively). Sixteen carcinomas (8%) scored only
weakly positive (total score 2–4): 5/79 SCC, 1/38 ASC,
and 10/75 AC samples (6%, 3%, and 13%, respectively).
Sixty-seven (35%) carcinomas scored moderately posi-
tive (total score 5–6), including 32/79 SCC, 12/38
ASC, and 23/75 AC cases (41%, 32%, and 31%, re-
spectively). Finally, 86 (45%) carcinomas scored strong
positive (total score 7–8), including 30/79 SCC, 16/38
ASC, and 40/75 AC cases (38%, 42%, and 53%,
respectively).
To assess whether HLA-E expression was associated
with clinical or histopathological parameters, the expres-
sion scores were dichotomized based on the median to
generate a cut-off score of 6, where a final score of≥6
indicated high HLA-E expression (N= 107, 56%) and a
final score of <6 indicated low to negative HLA-E ex-
pression (N= 85, 44%). Table 2 contains the associations
between HLA-E expression and histopathological para-
meters. HLA-E expression was significantly higher in
cervical AC than in cervical SCC and ASC (P= 0.010).
In addition, high expression of HLA-E was negatively
associated with LVSI (P= 0.045).Association between HLA-E expression and survival
Univariate and multivariate analyses were performed to
determine whether HLA-E expression was associated
with disease-specific and recurrence-free survival in cer-
vical cancer patients. Figure 2A and 2B contain the
Kaplan-Meier survival curves for disease-specific and
recurrence-free survival of all patients included in this
study, with separated lines for the histopathological
subtypes.
Figure 1 HLA-E expression in cervical epithelium and cervical carcinoma. Human leukocyte antigen E (HLA-E) immunohistochemistry was
performed with the MEM-E/02 antibody against HLA-E. A) Weak HLA-E expression in normal cervical squamous epithelium. B) Weak HLA-E
expression in normal cervical cylindrical epithelium. C) Strong HLA-E expression in endocervical-type cervical adenocarcinoma (AC) D) Strong
HLA-E expression in endometrioid-type AC. E) Moderate HLA-E expression in endocervical-type AC with normal stromal expression. F) Moderate
HLA-E expression in endocervical-type AC with strong stromal expression. G) Weak to negative HLA-E expression in endocervical-type AC. H)
Strong HLA-E expression in cervical squamous cell carcinoma. I) Weak to negative HLA-E expression in cervical squamous cell carcinoma. Bar
(blue, left bottom) represents 100 μm.
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disease-specific survival (Figures 2C, E, and G) and
recurrence-free survival (Figures 2D, F, and H) are shown
for high versus low HLA-E expression in SCC (2C, 2D),
ASC (2E, 2F), and AC patients (2G, 2H). Neither disease-
specific survival nor recurrence-free survival was signifi-
cantly different for high HLA-E expression versus low
HLA-E expression when comparing all histopathological
subtypes (P= 0.113 and P=0.079, respectively). However,
stratifying by histopathological subtype revealed that highHLA-E expression was strongly associated with improved
disease-specific and recurrence-free survival in cervical
AC (P=0.005 and P=0.001, respectively), but not in cer-
vical SCC or ASC subtype.
Risk was examined in a multivariate Cox regression
analysis for disease-specific survival and recurrence-free
survival, correcting for age, FIGO stage, histopatho-
logical subtype, tumour size, infiltration depth, LVSI,
tumour positive resection margins, tumour positive
parametrial infiltration, lymph node metastasis and
Table 2 Associations between HLE-E expression and histopathological parameters
HLA-E low HLA-E high P value
n (%) n (%)
Histology SCC 42 (53) 037 (47) 0.010
(n = 192) ASC 20 (53) 018 (47)
AC 23 (31) 052 (69)
Tumour stage FIGO I 72 (44) 093 (56) 0.662
(n = 192) FIGO II 13 (48) 14 (52)
HPV Negative 07 (44) 009 (56) 0.965
(n = 192) Positive 78 (44) 98 (56)
HPV type specific HPV 16 42 (43) 056 (57) 0.949
(n = 151) HPV 18 23 (43) 30 (57)
Tumour size <40 mm 56 (45) 069 (55) 0.997
(n = 183) >= 40 mm 26 (45) 32 (55)
Infiltration depth <15 mm 47 (40) 070 (60) 0.112
(n = 186) >= 15 mm 36 (52) 33 (48)
LVSI Negative 32 (38) 053 (62) 0.045
(n = 174) Positive 47 (53) 42 (47)
Resection margins Tumour free 62 (42) 086 (58) 0.178
(n = 191) Tumour positive 23 (54) 20 (47)
Parametria involvement Tumour free 76 (43) 100 (57) 0.314
(n = 192) Infiltrated 9 (56) 7 (44)
Lymph nodes Negative 60 (43) 081 (57) 0.426
(n = 192) Positive 25 (49) 26 (51)
Adjuvant radiotherapy No 37 (39) 059 (61) 0.110
(n = 192) Yes 48 (50) 48 (50)
Human leukocyte antigen E (HLA-E) expression scores are dichotomized by the median; a final score ≥6 indicates high HLA-E expression, and a final score <6
indicates low to negative HLA-E expression. For nine, six, eighteen, and one cases the tumour size, depth of infiltration, LVSI (lymph-vascular space invasion), and
tumour positivity of resection margins, respectively, could not be identified. P values were calculated using the Pearson Chi-Square test. P values in bold type
were considered statistically significant (P< 0.05). SCC, cervical squamous cell carcinoma; ASC, cervical adenosquamous carcinoma; AC, cervical adenocarcinoma;
FIGO, International Federation of Gynaecology and Obstetrics; HPV, human papillomavirus.
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significantly associated with disease-specific (hazard
ratio (HR) 0.74 (95% CI 0.39-1.42), P= 0.368) or
recurrence-free survival (HR 0.67 (0.36-1.24), P= 0.201).
However, after correction, tumour size (HR 1.05 (1.03-
1.07), P= 0.000) and HR 1.05 (1.03-1.07), P= 0.000),
tumour positive parametria (HR 2.30 (0.89-5.94),
P= 0.087 and HR 3.01 (1.21-7.49), P= 0.018) and lymph
node metastasis (HR 4.31 (2.07-8.95), P= 0.000 and HR
3.40 (1.69-6.86), P= 0.001) were strong independent pre-
dictors for disease-specific and recurrence-free survival.
Moreover, the AC histopathological subtype was also a
strong and independent predictor for disease-specific
(HR 2.79 (1.16-6.70), P= 0.022) and recurrence-free sur-
vival (HR 3.26 (1.48-7.18), P= 0.003).Discussion
Over the last few decades, rising incidence rates of cer-
vical AC have been observed relative and absolute to the
decreasing incidence rates of cervical SCC, predominantly
in younger women and in developed countries [5-9].
Evidence is accumulating that cervical AC is a distinct
clinical entity [10,11].In the present study we have detected high expres-
sion of HLA-E in the majority of the three most
common histopathological subtypes of cervical cancer.
Interestingly, high expression of HLA-E was more
frequently observed in cervical AC than in SCC and
ASC. High expression of HLA-E in AC was strongly
associated with favourable disease-specific and
recurrence-free survival. Given the rising incidence
rates of cervical AC, it is important to distinguish
this histopathological variant from the more common
SCC variant.
In most studies concerning cervical cancer, the majority
of included tumours are of the SCC subtype, whereas the
less-common AC and ASC subtypes comprise only a mi-
nority of cases. Moreover, in most studies the AC and
ASC cases are combined into one A(S)C subgroup. In this
report we compared large and well-defined cohorts of AC
and ASC cases with a reference cohort of SCC cases; the
SCC and ASC subtypes were accurately distinguished
from each other by PAS+/AB staining. Furthermore, the
AC subtypes included in this investigation were only the
most common and HPV-related AC subtypes: “usual-
type” endocervical AC, intestinal-type AC, mucinous AC
(not otherwise specified), and endometrioid-type AC [2,4].
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Figure 2 Disease-specific and recurrence-free survival curves.
Disease-specific survival curves (A, C, E, G) and recurrence-free
survival curves (B, D, F, H) for all cervical cancer patients included in
this study with separate lines for histopathological subtypes (A, B)
and for high versus low HLA-E expression shown for the
histopathological subtypes separately: cervical squamous cell
carcinomas (SCC; C, D), cervical adenosquamous carcinomas (ASC; E,
F), and cervical adenocarcinomas (AC; G, H). Disease-specific survival
was defined as time (months) from date of primary surgery until
death by cervical cancer or date of last follow-up. Recurrence-free
survival was defined as time (months) from date of primary surgery
until date of first recurrence or date of last follow-up in case of no
recurrence. HLA-E expression scores are dichotomized by the
median; HLA-E high represents a final expression score ≥6 and
HLA-E low represents a final expression score <6. Survival curves are
generated by the Kaplan-Meier method and P values are calculated
by the Log Rank (Mantel-Cox) test.
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histopathological subtypes in this study. In concordance
with previous reports, the AC patients and the ASC
patients were significantly younger at time of diagnosis
than the SCC patients (mean ages 44 and 43 years versus
50 years, respectively) [5,28,29]. Why AC and ASC present
more frequently at a younger age is currently unclear.
Tumour size, tumour infiltration depth, and LVSI also sig-
nificantly differed between the histopathological subtypes,
with SCC being larger and more invasive than ASC and
AC. This observation is important, as it is the size of the
tumour, its depth of invasion, and the presence of LVSI
that predict prognosis in many cases [4].
The most important prognostic histopathological fac-
tors, tumour stage and lymph node status, were equally
distributed between the histopathological subgroups in
this study. However, selection of patients with tumour-
positive lymph nodes revealed a clear trend: the worst
recurrence-free survival rates occurred for ASC patients,
followed by AC patients and a more favourable
recurrence-free survival for SCC patients (P= 0.058; data
not shown). In addition, multivariate Cox survival ana-
lysis indicated that histopathological subtype is an inde-
pendent prognostic factor for survival, with worse
disease-specific and recurrence-free survival for the ASC
and AC subtypes (hazard ratios for disease-specific sur-
vival, 2.15 and 2.79 respectively; for recurrence-free sur-
vival, 2.00 and 3.26, respectively; hazard ratios are
relative to SCC).
Cervical cancer is induced by persistent infection with
HPV, although different associations with HPV have
been described for distinct histopathological subtypes
[14,30]. In our study, HPV positivity and the distribution
of HPV types also differed significantly among the histo-
pathological subgroups. A high-risk HPV type was
detected in 95-97% of all SCC and ASC patients, but
only 85% of the AC patients. A possible explanation for
the higher rate of HPV-negative cases in AC is that glan-
dular cells support a productive HPV infection to a
lesser extent, leading to a low viral load in AC. The de-
tection of a positive high-risk HPV infection in cervical
AC can therefore be more difficult compared to SCC
and ASC [13,31]. In agreement with the literature, in
this study HPV 16 was the most frequently detected type
in 68% of the SCC cases, 51% of the ASC cases, and 44%
of the AC cases, followed by HPV 18 (17% SCC, 32%
ASC, and 44% AC). Only 12% of the AC cases were
caused by infections with HPV other than types 16 and
18 (mainly HPV 45), compared to 15% and 16% of the
SCC and ASC cases, respectively.
The immune system plays an important role in the pro-
gression from initial HPV infection to the development of
cervical cancer [17]. The non-classical HLA class Ib mol-
ecule HLA-E is involved in the immunological response in
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This study was designed to determine the differences in
HLA-E expression in the three most common histopatho-
logical subtypes of cervical cancer. High expression of
HLA-E was found in 56% of all cases. We confirmed our
previous observation of HLA-E expression in SCC [23],
and demonstrated high expression of HLA-E in ASC and
AC. Furthermore, high expression of HLA-E was more
frequently observed in AC than in SCC and ASC (69% vs.
47% and 47%, respectively; P=0.010). We also noted that
high expression of HLA-E was associated with negative
LVSI (62%, P=0.045). However, the function of high
HLA-E expression on cervical tumour cells and on the
tumour cells of cervical AC in particular remains
uncertain.
Previously, increased expression of HLA-E in several
malignant cell types was described in combination with
down-regulation of other HLA class I proteins [22,32].
HLA-E function has been investigated in the context of
HPV, hepatitis C virus, human cytomegalovirus, human
immunodeficiency virus, Epstein-Barr virus, and influ-
enza virus infections [22], leading to the hypothesis that
viral peptides are bind to HLA-E, upregulate its surface
expression, and lead to the inhibition of NK cells
through binding to the CD94/NKG2A receptor. Com-
bined with the decreased surface expression of HLA
class I molecules, the infected (tumour) cells gradually
lose their capacity for HLA class I peptide presentation
to CTLs and subsequently escape from immune attack
[24,33-36].
We have previously shown that there are a high num-
ber of CTLs in the tumour cell nests and tumour stroma
of cervical carcinomas [26]. However, as in most solid
tumours, NKs barely infiltrate these tumours [23,37].
Furthermore, tumour-infiltrating CTLs in cervical car-
cinomas lack expression of the activating receptor
CD94/NKG2C, but, in contrast, do express the inhibit-
ing receptor CD94/NKG2A [23,38]. Upregulation of this
inhibiting receptor on CTLs can also be induced by the
multifunctional cytokine transforming growth factor-
beta (TGF-β) [38], which critically contributes to cervical
carcinogenesis [39-41]. However, in cervical AC, activa-
tion of the TGF-β pathway is more frequently impaired
than in SCC [unpublished data]. This observation may
imply that the CD94/NKG2A receptor is less abundantly
expressed on CTLs in cervical AC, leading to less bind-
ing of HLA-E and increased effector function [18,38].
In this study, high HLA-E expression was associated
with better long-term disease-specific and recurrence-
free survival in the cervical AC subtype. However, this
effect disappeared in the multivariate analysis, where
only histopathological subtype, tumour size, tumour-
positive parametrial infiltration, and tumour-positive
lymph nodes were independent predictors for survivaland recurrent disease. Studies concerning the prognostic
value of HLA-E expression are controversial. Associa-
tions between HLA-E expression and improved survival
have been described for colorectal carcinoma [42-44],
breast carcinoma [45], and glioblastoma [46]. Several
studies have reported that HLA-E overexpression is cor-
related with tumour progression, exhibiting a trend to-
ward worse survival [43-45]. Some reports speculate that
high HLA-E expression by malignant cells may represent
a selective pro-host advantage, possibly related to a bet-
ter response rate to subsequent therapies [46]. Benevolo
et al. interpret their measurements of HLA-E expression
in colorectal carcinoma by the immunoediting model
[47], proposing a dual outcome model in which HLA-E
is on one hand the first immunological control for HLA-
edited tumour variants and on the other hand a trigger
for active immune responses [42]. Here, we also suggest
that the inhibiting and activating functions of HLA-E
may be related to the delicate balance between immune
escape and immune surveillance in cervical tumours.
However, functional studies will be needed to further
unravel the role of HLA-E expression and the underlying
mechanisms in cervical cancer and in cervical AC in
particular. In most studies, cervical AC comprises only
the minority of cases; therefore a multicenter study
would be highly valuable to obtain more AC cases.Conclusion
In summary, this investigation was the first study of
HLA-E expression in a large and well-defined cohort of
cervical AC, ASC, and SCC patients. High expression
of HLA-E occurred in 53% of all histopathological sub-
types. In cervical AC specifically, a significantly higher
rate of high HLA-E expression was associated with
improved long-term disease-specific and recurrence-free
survival. In addition, this study also highlights the im-
portance of careful and reliable histopathological evalu-
ation to precisely define histopathological tumour
subtypes. Insight into the biological behaviour and the
distinct molecular carcinogenetic processes of the AC,
ASC, and SCC subtypes may contribute to the develop-
ment of tumour-specific treatment strategies, future vac-
cine development, and the design of tumour-specific
immunotherapies.Abbreviations
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